Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Poster presentation at the International Congress of the Society for Melanoma Research in 2022

We are proud to report another successful international poster presentation on an European Melanoma Registry project. Following the two EUMelaReg projects EMR-SEQ and EMR-PD1, this year's International Congress of the Society for Melanoma Research in Edinburgh saw the presentation of the results of the project: "Adjuvant use of pembrolizumab in stage III melanoma in a real-world setting in Europe."

Although data on patients treated with pembrolizumab are available from clinical trials and reports from individual countries, to our knowledge there have been no cross-national studies investigating the use of pembrolizumab as an adjuvant treatment for stage III melanoma. We used EUMelaReg to analyse patients with stage III melanoma with complete resection who received adjuvant treatment with pembrolizumab according to SmPC. Major questions to be addressed were whether real-world usage would resemble key findings received from clinical trials in the respective populations.

We would like to thank everyone who contributed to this project and look forward to collaborating on future projects.